Inflabloc Pharmaceuticals Inc. Closes $6 Million Series C Financing And Merger With MantiCore Pharmaceuticals Inc.

SALT LAKE CITY--(BUSINESS WIRE)--Feb. 9, 2006--Inflabloc Pharmaceuticals Inc. announced today that it had successfully completed a $6 million Series C venture financing. This financing coincides with the completion of the merger with MantiCore Pharmaceuticals Inc. and was co-led by Friedli Corporate Finance and vSpring Capital. Inflabloc will use the financing to further its Phase II clinical studies of its lead product targeting inflammatory diseases, as well as continue early-stage development in oncological diseases.